Investigational drug plus lenvatinib for penile cancer that has been treated before
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a combination of two drugs, QL1706 and lenvatinib, in people with penile cancer that has already been treated with other therapies. The goal is to see if this new combination can shrink tumors or slow cancer growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have penile cancer that is a type called squamous cell carcinoma.
- You have already received at least one prior treatment, such as chemotherapy, immunotherapy, or targeted therapy.
- You have at least one tumor that can be measured on scans.
- Your overall health status allows you to be up and about most of the day (ECOG score 0-2).
- You have adequate blood cell counts and kidney/liver function (tests will confirm).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination treatment for advanced penile cancer that hasn't been treated before. It combines a targeted drug (becotatug vedotin) designed to attack cancer cells with an immunotherapy drug (pucotenlimab) that helps your immune system fight cancer.
This trial tests a combination of two chemotherapy drugs (carboplatin and paclitaxel) plus the immunotherapy drug pembrolizumab (Keytruda) for penile cancer that has spread to nearby lymph nodes. The goal is to see if this combination can shrink or control the cancer before or after surgery.
This trial tests a combination of three drugs (QL1706, lenvatinib, and chemotherapy) as the first treatment for people with advanced pancreatic cancer that has spread to other parts of the body. It aims to see if this combination is safe and effective.
This trial tests a new combination treatment before surgery for liver cancer. It aims to shrink tumors and reduce the chance of cancer coming back after surgery.
This trial tests a combination of two drugs, lenvatinib (a targeted therapy that stops blood vessel growth to tumors) and a PD-1 inhibitor (an immunotherapy that helps your immune system fight cancer), in people with advanced solid tumors that have a specific genetic change called 11q13 amplification. The goal is to see if this combination can shrink or control tumors that haven't responded to other treatments.
This trial tests a new combination of two drugs (QL1706 and lenvatinib) for people whose esophageal cancer has progressed after initial immunotherapy. The goal is to see if this combination can help shrink tumors or slow cancer growth.
Hear when a new Penile Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.